346 related articles for article (PubMed ID: 15729374)
21. Erectile dysfunction, sildenafil and cardiovascular risk.
Langton PE
Med J Aust; 2000 Oct; 173(8):446. PubMed ID: 11090041
[No Abstract] [Full Text] [Related]
22. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials.
Blonde L
Curr Med Res Opin; 2006 Nov; 22(11):2111-20. PubMed ID: 17076971
[TBL] [Abstract][Full Text] [Related]
23. [Viagra landing: the dawn of sexual science in cardiology].
Ishikura F
J Cardiol; 1999 Sep; 34(3):163-7. PubMed ID: 10500978
[No Abstract] [Full Text] [Related]
24. PDE5 inhibitors: are there differences?
Carson CC
Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
[TBL] [Abstract][Full Text] [Related]
25. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
[TBL] [Abstract][Full Text] [Related]
26. Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy.
Nehra A; Grantmyre J; Nadel A; Thibonnier M; Brock G
J Urol; 2005 Jun; 173(6):2067-71. PubMed ID: 15879836
[TBL] [Abstract][Full Text] [Related]
27. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
Ströberg P; Hedelin H; Ljunggren C
Eur Urol; 2006 May; 49(5):900-7; discussion 907. PubMed ID: 16564126
[TBL] [Abstract][Full Text] [Related]
28. Erectile dysfunction and coronary atherothrombosis in diabetic patients: pathophysiology, clinical features and treatment.
Gazzaruso C
Expert Rev Cardiovasc Ther; 2006 Mar; 4(2):173-80. PubMed ID: 16509813
[TBL] [Abstract][Full Text] [Related]
29. Emergence and success of PDE5 inhibitors as effective therapy for erectile dysfunction.
Manganiello V
Int J Impot Res; 2004 Jun; 16 Suppl 1():S1-3. PubMed ID: 15224126
[No Abstract] [Full Text] [Related]
30. Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
Kukreja RC; Ockaili R; Salloum F; Yin C; Hawkins J; Das A; Xi L
J Mol Cell Cardiol; 2004 Feb; 36(2):165-73. PubMed ID: 14871543
[TBL] [Abstract][Full Text] [Related]
31. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).
Kostis JB; Jackson G; Rosen R; Barrett-Connor E; Billups K; Burnett AL; Carson C; Cheitlin M; Debusk R; Fonseca V; Ganz P; Goldstein I; Guay A; Hatzichristou D; Hollander JE; Hutter A; Katz S; Kloner RA; Mittleman M; Montorsi F; Montorsi P; Nehra A; Sadovsky R; Shabsigh R
Am J Cardiol; 2005 Jul; 96(2):313-21. PubMed ID: 16018863
[TBL] [Abstract][Full Text] [Related]
32. Sildenafil: emerging cardiovascular indications.
Raja SG; Nayak SH
Ann Thorac Surg; 2004 Oct; 78(4):1496-506. PubMed ID: 15464535
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.
Kloner RA
Circulation; 2004 Nov; 110(19):3149-55. PubMed ID: 15533876
[No Abstract] [Full Text] [Related]
34. [Levitra (vardenafil)--a new PDE 5 inhibitor for the treatment of erectile dysfunction].
Katsarov M
Akush Ginekol (Sofiia); 2004; 43 Suppl 1():31-2. PubMed ID: 15323315
[No Abstract] [Full Text] [Related]
35. Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels.
Carosa E; Martini P; Brandetti F; Di Stasi SM; Lombardo F; Lenzi A; Jannini EA
Clin Endocrinol (Oxf); 2004 Sep; 61(3):382-6. PubMed ID: 15355456
[TBL] [Abstract][Full Text] [Related]
36. Acute myocardial infarction after sildenafil citrate ingestion.
Kekilli M; Beyazit Y; Purnak T; Dogan S; Atalar E
Ann Pharmacother; 2005; 39(7-8):1362-4. PubMed ID: 15914518
[TBL] [Abstract][Full Text] [Related]
37. Phosphodiesterase 5 inhibition: effects on the coronary vasculature.
Jackson G
Int J Clin Pract; 2001 Apr; 55(3):183-8. PubMed ID: 11351772
[TBL] [Abstract][Full Text] [Related]
38. Vasoactive pharmacotherapy to cure erectile dysfunction: fact or fiction?
Burnett AL
Urology; 2005 Feb; 65(2):224-30. PubMed ID: 15708027
[No Abstract] [Full Text] [Related]
39. Phosphodiesterase type 5 inhibitors for erectile dysfunction.
Carson CC; Lue TF
BJU Int; 2005 Aug; 96(3):257-80. PubMed ID: 16042713
[TBL] [Abstract][Full Text] [Related]
40. Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction.
Salem EA; Kendirci M; Hellstrom WJ
Curr Opin Investig Drugs; 2006 Jul; 7(7):661-9. PubMed ID: 16869121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
